Antioxidant and anti-inflammatory role of paraoxonase 1: Implication in arteriosclerosis diseases

North American Journal of Medical Sciences

Volumn 4, Issue 11, 2012, Pages 523-532

  Litvinov, Dmitry ^a   Mahini, Halleh ^b   Garelnabi, Mahdi ^b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

Author keywords

Antioxidants; Atherosclerosis; Cardiovascular disease; Coronary artery disease; PON1

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; BERBERINE; COMPLEMENTARY DNA; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; POLYPHENOL DERIVATIVE; PROTEIN C JUN; PROTEIN KINASE C; SALICYLIC ACID;

ALLELE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIOSCLEROSIS; ARTICLE; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC); NONHUMAN; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PROTEIN POLYMORPHISM; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; WESTERN BLOTTING;

EID: 84869402322     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.103310     Document Type: Article

References (72)

1. Primo-Parmo SL, Sorenson RC, Teiber JF, La Du BN, The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507.
2. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412-419.
3. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specifcities. J Lipid Res 2005;46:1239-1247.
4. Khersonsky O, Tawfk DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005;44:6371-6382.
5. Kerkeni M, Addad F, Chauffert M, Chuniaud L, Miled A, Trivin F, et al. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 2006;39:821-825.
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
7. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modifcation of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-283.
8. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-154.
9. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-1590.
10. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modifcation by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-135.
11. Watson DD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-2891.
12. Teiber JF, Draganov DI, La Du BN. Purifed human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res 2004;45:2260-2268.
13. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-287.
14. Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: Studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005;181:9-18.
15. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry 1991;30:10141-10149.
16. Mackness B, Beltran-Debon R, Aragones G, Joven J, Camps J, Mackness M. Human tissue distribution of paraoxonases 1 and 2 mRNA. IUBMB Life 2010;62:480-482.
17. Shamir R, Hartman C, Karry R, Pavlotzky E, Eliakim R, Lachter J, et al. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: Selective secretion of PON1 and PON2. Free Radic Biol Med 2005;39:336-344.
18. Brophy HV, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001;11:77-84.
19. Ikeda Y, Suehiro T, Arii K, Kumon Y, Hashimoto K. High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes. Metabolism 2008;57:1725-1732.
20. Osaki F, Ikeda Y, Suehiro T, Ota K, Tsuzura S, Arii K, et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 2004;176:279-287.
21. Ota K, Suehiro T, Arii K, Ikeda Y, Kumon Y, Osaki F, et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 2005;54:142-150.
22. Arii K, Suehiro T, Ota K, Ikeda Y, Kumon Y, Osaki F, et al. Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 2009;202:439-445.
23. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: A role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003;23:2083-2089.
24. Gouédard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol 2004;24:5209-5222.
25. Jaichander P, Selvarajan K, Garelnabi M, Parthasarathy S. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res 2008;49:2142-2148.
26. Gouédard C, Barouki R, Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol 2004;24:2378-2383.
27. Cheng CC, Hsueh CM, Liang KW, Ting CT, Wen CL, Hsu SL. Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells. Eur J Pharmacol 2011;650:519-525.
28. Gutierrez A, Ratliff EP, Andres AM, Huang X, McKeehan WL, Davis RA. Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4. Arterioscler Thromb Vasc Biol 2006;26:301-306.
29. Shih DM, Kast-Woelbern HR, Wong J, Xia YR, Edwards PA, Lusis AJ. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J Lipid Res 2006;47:384-392.
30. Gonzalvo MC, Gil F, Hernandez AF, Rodrigo L, Villanueva E, Pla A. Human liver paraoxonase (PON1): Subcellular distribution and characterization. J Biochem Mol Toxicol 1998;12:61-69.
31. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affnity, saturable, desorption mechanism. J Biol Chem 2002;277:4301-4308.
32. Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005;179:17-25.
33. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999;19:2214-2225.
34. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993;365:762-764.
35. Gaidukov L, Tawfk DS. High affnity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005;44:11843-11854.
36. Gaidukov L, Viji RI, Yacobson S, Rosenblat M, Aviram M, Tawfk DS. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I. Biochemistry 2010;49:532-538.
37. Noto H, Hashimoto Y, Satoh H, Hara M, Iso-o N, Togo M, et al. Exclusive association of paraoxonase 1 with high-density lipoprotein particles in apolipoprotein A-I deficiency. Biochem Biophys Res Commun 2001;289:395-401.
38. Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: A new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res 2004;95:789-797.
39. Escolà-Gil JC, Marzal-Casacuberta A, Julve-Gil J, Ishida BY, Ordóñez-Llanos J, Chan L, et al. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: Evidence of a potentially relevant species-specifc interaction with diet. J Lipid Res 1998;39:457-462.
40. Deakin SP, Bioletto S, Bochaton-Piallat ML, James RW. HDL-associated paraoxonase-1 can redistribute to cell membranes and infuence sensitivity to oxidative stress. Free Radic Biol Med 2011;50:102-109.
41. Fuhrman B, Volkova N, Aviram M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 2005;180:55-61.
42. Rodrigo L, Hernández AF, López-Caballero JJ, Gil F, Pla A. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 2001;137:123-137.
43. Marsillach J, Mackness B, Mackness M, Riu F, Beltrán R, Joven J, et al. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med 2008;45:146-157.
44. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:1233-1238.
45. Marsillach J, Camps J, Beltran-Debón J, Rull A, Aragones G, Maestre-Martínez C, et al. Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. Eur J Clin Invest 2011;41:308-314.
46. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996;97:1630-1639.
47. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000;275:17527-17535.
48. Ng DS, Chu T, Esposito B, Hui P, Connelly PW, Gross PL. Paraoxonase-1 defciency in mice predisposes to vascular infammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc Pathol 2008;17:226-232.
49. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 2002;290:921-927.
50. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002;106:484-490.
51. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:1545-1550.
52. Guns PJ, Van Assche T, Verreth W, Fransen P, Mackness B, Mackness M, et al. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br J Pharmacol 2008;153:508-516.
53. Wang M, Lang X, Cui S, Zou L, Cao J, Wang S, et al. Quantitative Assessment of the Infuence of Paraoxonase 1 Activity and Coronary Heart Disease Risk. DNA Cell Biol 2012;31:975-982.
54. Zhao Y, Ma Y, Fang Y, Liu L, Wu S, Fu D, et al. Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies. Mol Genet Metab 2012;105:141-148.
55. Wang Y, Fu W, Xie F, Wang Y, Chu X, Wang H, et al. Common polymorphisms in ITGA2, PON1 and THBS2 are associated with coronary atherosclerosis in a candidate gene association study of the Chinese Han population. J Hum Genet 2010;55:490-494.
56. Gungor O, Kircelli F, Demirci MS, Tuncel P, Sisman AR, Tatar E, et al. Serum paraoxonase 1 activity predicts arterial stiffness in renal transplant recipients. J Atheroscler Thromb 2011;18:901-905.
57. Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD. Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS One 2011;6:e17805.
58. Gupta N, Binukumar BK, Singh S, Sunkaria A, Kandimalla R, Bhansali A, et al. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population. Gene 2011;487:88-95.
59. Coombes RH, CrowJA, Dail MB, Chambers HW, Wills RW, Bertolet BD, et al. Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South. Pharmacogenet Genomics 2011;21:867-875.
60. Likidlilid A, Akrawinthawong K, Poldee S, Sriratanasathavorn C. Paraoxonase 1 polymorphisms as the risk factor of coronary heart disease in a Thai population. Acta Cardiol 2010;65:681-691.
61. Lüersen K, Schmelzer C, Boesch-Saadatmandi C, Kohl C, Rimbach G, Döring F. Paraoxonase 1 polymorphism Q192R affects the pro-infammatory cytokine TNF-alpha in healthy males. BMC Res Notes 2011;4:141.
62. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001;68:1428-1436.
63. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997;17:2935-2939.
64. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997;122:265-268.
65. Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE. Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. Curr Protoc Toxicol 2004; Chapter 4:Unit 4.12.
66. Bayrak A, Bayrak T, Demirpençe E, Kilinç K. Differential hydrolysis of homocysteine thiolactone by purifed human serum (192)Q and (192)R PON1 isoenzymes. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:49-55.
67. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modifcation. FEBS Lett 1998;423:57-60.
68. Dahabreh IJ, Kitsios GD, Kent DM, Trikalinos TA. Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Genet Med 2010;12:606-615.
69. Banerjee I. Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: A meta-analysis. Eur J Epidemiol 2010;25:449-458.
70. Wang M, Lang X, Zou L, Huang S, Xu Z. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: A meta-analysis based on 88 case-control studies. Atherosclerosis 2011;214:377-385.
71. Lawlor DA, Day IN, Gaunt TR, Hinks LJ, Briggs PJ, Kiessling M, et al. The association of the PON1 Q192R polymorphism with coronary heart disease: Findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet 2004;5:17.
72. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: Meta-analysis of 43 studies. Lancet 2004;363:689-695.